Kupando raises €13.0M Series A round
26 September 2022· Schönefeld, Germany· health, biotech, oncology, b2b, deep_hardware
The funds will be used to complete IND-enabling work and to initiate the clinical development of Kupando's lead candidate KUP101 in a solid tumor indication.
Investors
LeadRemiges Ventures
Also participating
High-Tech GründerfondsBrandenburg KapitalLifeCare PartnersCoparionVentura BioMed Investors
About Kupando
Stage
Series A
Headquarters
Schönefeld, Germany
Founded
2018
Team Size
21–50
Sectors
healthbiotechoncologyb2bdeep_hardware
Source: https://www.kupando.com/press-releases/kupando-raises-e13-million-in-series-a-funding-round/